CEL-SCI Corporation Receives Exemption⁢ for Pediatric Trials of Multikine in the‍ UK

CEL-SCI Corporation (NYSE American: CVM), a biotechnology company based in Vienna, Virginia, ⁣has announced that it has received an exemption from the UK Healthcare Products Regulatory Agency (MHRA) for pediatric trials of its investigational ⁣anti-cancer drug, Multikine,‌ in head and‍ neck cancer.

The exemption eliminates the need for CEL-SCI ​to conduct clinical trials of Multikine in patients under the age of 18 as part of the UK marketing authorization process. This decision marks a significant step forward ⁢for CEL-SCI in bringing Multikine to the UK market.

About Multikine

Multikine (Leukocyte Interleukin, ⁢Injection) is being developed as ‌a first-line cancer treatment and has been administered to over 740 patients‌ to⁢ date. ⁣The treatment has been granted orphan drug designation by the FDA as a neoadjuvant⁢ treatment for⁤ patients ‌with‍ head and neck squamous cell carcinoma.

According to CEL-SCI, Multikine significantly increased the survival rate of patients in clinical trials,⁢ with a 5-year survival⁣ rate of‍ 73% compared to 45% for patients who did not receive Multikine. Based on these results, the FDA agreed with the company’s⁤ patient selection criteria for the registration trial, which ⁢is scheduled to enroll 212‍ patients.

CEL-SCI’s​ Mission

CEL-SCI emphasizes that strengthening a patient’s immune system ‍early⁣ in cancer treatment is important to improve their chances of survival. The company ⁤is committed to advancing its investigational cancer drug, Multikine, and bringing it⁣ to market⁤ to help patients with head and⁣ neck​ cancer.

Recent Developments

CEL-SCI has announced a public offering ‍of 10,845,000 shares, which will be used to fund the development ⁣of⁣ its lead ⁤investigational drug, Multikine, general ‍corporate needs, and working ⁤capital. Additionally, the⁣ company reported favorable results from a comprehensive bias analysis of a‌ Phase 3 trial of⁤ Multikine, a potential immunotherapy for head and neck cancer.

The analysis showed ​no significant difference between the‍ treatment and control groups,⁢ supporting the clinical efficacy of Multikine in ​extending patient‍ survival. Following these developments, the FDA granted CEL-SCI approval for a confirmatory registrational⁣ trial of ‍Multikine in newly diagnosed patients with⁤ no lymph node metastasis and low PD-L1 expression, a group that showed a significant survival benefit⁢ in the Phase 3 trial.

CEL-SCI’s⁤ Financial Position

CEL-SCI’s gross profit for the trailing 12 months as of the third quarter‍ of 2024 was negative $18.95 million, indicating the company’s ‍difficulty generating profits from its‌ business. Adjusted operating profit for the same period was also negative $27.7 million.

The market has reacted to‍ these financial figures ⁤with CEL-SCI shares falling⁣ sharply, with‌ the stock’s total⁢ return plummeting 53.25% over the past six months, highlighting the volatility ⁢and risk of investing in this biotech company at this‌ stage.

Analysts do not expect the company to be profitable this ‌year, and the company has not made a profit ⁣in the ⁢past 12 months. These insights, coupled with the⁤ company’s current financial data, can help investors make ‌more informed decisions.